Patents by Inventor Brett Coopers

Brett Coopers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200275799
    Abstract: Described herein is a cooking pot comprising (a) a food vessel that has an opening in the shape of an oval or a polygon with more than two sides, and (b) a lid sized and shaped to substantially cover the opening of the food vessel. According to some embodiments of the present disclosure, the lid has a ring protruding from the bottom face, concentric about a vertical axis of the vessel. When the lid is rotated about the vertical axis at an angle from a closed position, the protruding ring is positioned adjacent to an interior edge of the vessel, corners or vertices of the opening are uncovered, and corresponding corners or vertices of the lid hang over the vessel exterior.
    Type: Application
    Filed: February 27, 2020
    Publication date: September 3, 2020
    Inventors: Anthony CHIMBUYA, Bruce COOPER, David QUAN, Anthony WOLF, Helen KERR, Chay YOUNG LEE, Brett BELCHER
  • Publication number: 20200253983
    Abstract: The present invention relates to Orally Inhaled and Nasal Drug Product (OINDP) comprising a benzodiazepine, in particular remimazolam.
    Type: Application
    Filed: March 24, 2020
    Publication date: August 13, 2020
    Inventors: Karl-Uwe Petersen, Derek Jo Sakata, Thomas Stohr, John Graham, Brett Coopers, Tatjana Bevans, Christopher Reilly
  • Publication number: 20190175613
    Abstract: The present invention relates to Orally Inhaled and Nasal Drug Product (OINDP) comprising a benzodiazepine, in particular remimazolam.
    Type: Application
    Filed: April 18, 2017
    Publication date: June 13, 2019
    Applicant: Paion UK Limited
    Inventors: Karl-Uwe Petersen, Derek Jo Sakata, Thomas Stöhr, John Graham, Brett Cooper, Tatjana Bevans, Christopher Reilly
  • Patent number: 9937153
    Abstract: The present invention is directed to stable, oral pharmaceutical formulations of dipeptidyl peptidase-4 inhibitors, such as omarigliptin. Such pharmaceutical formulations comprise omarigliptin; and neutral excipients, wherein the neutral excipient is present in the amount of at least 75% by weight of the pharmaceutical formulation and comprises at least one non-reducible sugar diluent or a mixture of non-reducible sugar diluents.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: April 10, 2018
    Assignees: Merck Sharp & Dohme LTD., Merck Sharp & Dohme Corp.
    Inventors: Vincent Brett Cooper, Kathryn Alanna Bradley, Samuel Robert Pygall, Rajan Gupta, Madison Paige Stanford, Lin Xie
  • Publication number: 20160166544
    Abstract: The present invention is directed to stable, oral pharmaceutical formulations of dipeptidyl peptidase-4 inhibitors, such as omarigliptin. Such pharmaceutical formulations comprise omarigliptin; and neutral excipients, wherein the neutral excipient is present in the amount of at least 75% by weight of the pharmaceutical formulation and comprises at least one non-reducible sugar diluent or a mixture of non-reducible sugar diluents.
    Type: Application
    Filed: August 25, 2014
    Publication date: June 16, 2016
    Inventors: Vincent Brett Cooper, Kathryn Alanna Bradley, Samuel Robert Pygall, Rajan Gupta, Madison Paige Stanford, Lin Xie
  • Patent number: 8357798
    Abstract: Potassium salts of Compound A and methods for their preparation are disclosed, wherein Compound A is of formula: Compound A is an HIV integrase inhibitor useful for treating or prophylaxis of HIV infection, for delaying the onset of AIDS, and for treating or prophylaxis of AIDS.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: January 22, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kevin M. Belyk, Henry G. Morrison, Philip Jones, Vincenzo Summa, V. Brett Cooper, Amar J. Mahajan, Daniel J. Kumke, Hsien-Hsin Tung, Lawrence Wai, Vanessa Pruzinsky, Philip Pye, Remy Angelaud, Danny Mancheno
  • Patent number: 8236958
    Abstract: Two new crystalline monohydrates and two new crystalline anhydrates of gaboxadol are disclosed together with methods for preparing them.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: August 7, 2012
    Assignee: H. Lundbeck A/S
    Inventor: Vincent Brett Cooper
  • Publication number: 20120191500
    Abstract: A method for organizing meeting information, comprising: receiving information about a meeting utilizing a computer; creating a meeting space to represent the meeting, utilizing the computer; integrating known information about the meeting in the meeting space, utilizing the computer; searching for other information about the meeting utilizing the computer; adding any additional information found about the meeting in the meeting space, utilizing the computer; and managing the meeting space utilizing the computer.
    Type: Application
    Filed: December 13, 2011
    Publication date: July 26, 2012
    Inventors: Blake BYRNES, Brett COOPER, Richard MAKERSON, Jeffrey STEINKE
  • Patent number: 7865931
    Abstract: The invention provides a system that includes: a web server, an application server, and a data server all connected to each other. The system is intended to protect web based applications. A web server receives a request and transmits it as a message to the application server. When the application server receives the request, the application server extracts attributes of this request. The application server uses an authorization engine to determine if each attribute of the request is authorized by accessing the data server to compare each attribute of the request with at least one rule from a rules store. The rules store resides on the data server. If the attributes of the request meet the rules in the rules store, then the request is executed by the application server.
    Type: Grant
    Filed: November 25, 2002
    Date of Patent: January 4, 2011
    Assignee: Accenture Global Services Limited
    Inventors: Andrew Stone, Brett Cooper, Christopher Miller, Timothy Daniel McCarthy, Clifford Randall Cannon
  • Patent number: 7262300
    Abstract: Two new crystalline monhydrates and two new crystalline anhydrates of gaboxadol are disclosed together with methods for preparing them.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: August 28, 2007
    Assignee: Merck Sharp & Dohme Ltd.
    Inventor: Vincent Brett Cooper
  • Publication number: 20050246345
    Abstract: A system and method for configuring a storage network utilizing one or more storage appliances to utilize the multi-block based protocol nature of the storage appliances. By configuring the storage network, data served by the storage appliance may be accessed by a plurality of protocols simultaneously. Illustratively, a virtual disk (vdisk) may be access by clients using the FCP protocol over a FC network while other clients access the vdisk using the iSCSI protocol over a TCP/IP network.
    Type: Application
    Filed: April 30, 2004
    Publication date: November 3, 2005
    Inventors: Arthur Lent, Brett Cooper
  • Patent number: 6521625
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and are selected from the group consisting of 3-Fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide polymorphic crystalline Anhydrous Form B, 3-Fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide polymorphic crystalline form Type A Monohydrate, and 3-Fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide polymorphic crystalline form Type B monohydrate, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: February 18, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Cameron J. Cowden, V. Brett Cooper, Daniel J. Rush, Patricia Frech
  • Publication number: 20020004507
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and are selected from the group consisting of 3-Fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide polymorphic crystalline Anhydrous Form B, 3-Fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide polymorphic crystalline form Type A Monohydrate, and 3-Fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide polymorphic crystalline form Type B monohydrate, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 31, 2001
    Publication date: January 10, 2002
    Inventors: Cameron J. Cowden, V. Brett Cooper, Daniel J. Rush, Patricia Frech